GS
CBIO

George Soros’s Crescent Biopharma CBIO Stock Holding History

George Soros’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-103
Closed -$87K – 295
2014
Q2 		$87K Buy
+103
New +$103K ﹤0.01% 329

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.11B AUM 12.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $1.24B AUM 2.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

George Soros's CBIO Position: Q3 2014 in Review

George Soros sold out of Crescent Biopharma (CBIO) in Q3 2014, closing a stake of 103 shares — an estimated $87K sold.

George Soros first reported a position in CBIO in Q2 2014 and held it in 1 quarter. The position peaked at $87K in Q2 2014. 27 funds tracked by Wall St. Rank hold CBIO as of Q3 2014.

  • George Soros reported no remaining Crescent Biopharma position as of Q3 2014 after selling out during the quarter.
  • George Soros sold 103 Crescent Biopharma shares in Q3 2014, an estimated $87K.
  • George Soros first reported a position in Crescent Biopharma in Q2 2014 and held it in 1 quarter.
  • George Soros's Crescent Biopharma position peaked at $87K in Q2 2014.
  • 27 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2014.

Based on Soros Fund Management's 13F filing for Q3 2014, filed 14 Nov 2014.